Print this page    •   Back to Web version of article

AIDS Drug Assistance Program (ADAP) Funding Overview

2003

The CARE Act is the largest source of Federal funding specifically directed to provide primary care and support services for low-income, uninsured, and under-insured persons living with HIV disease. Under Title II of the CARE Act, formula grants are awarded to States and eligible U.S. Territories to improve the quality, availability, and organization of HIV health care and support services. In addition to other specific service programs, Title II funds AIDS Drug Assistance Programs (ADAPs). ADAPs provide medications to low-income individuals with HIV disease who have limited or no coverage from private insurance or Medicaid, in all 50 States, the District of Columbia, Puerto Rico, the Virgin Islands, and Guam. Territories including American Somoa, the Commonwealth of the Northern Mariana Islands, Palau, the Federated States of Micronesia and the Republic of the Marshall Islands are also eligible to establish ADAPs.


Increased Demand for ADAPs

The last several years have seen an unprecedented growth in client demand and program costs for ADAPs. This is due to:

Future demand on ADAP resources is expected to escalate as the standard of care improves for people with HIV/AIDS and as patients continue to respond to new drug therapies.


Overview of Funding

In response to the increased demand, Federal and other funding of ADAPs have grown significantly (see chart). Federal sources of ADAP funding include:

States also allocate general revenue or other State funds to support their ADAPs. In FY 2003, 37 States projected the appropriation of State funds to ADAPs. In addition, ADAPs use various cost-containment strategies that maximize funds, allowing ADAPs to serve more people living with HIV/AIDS.


AIDS Drug Assistance Program (ADAP): Total Funding -- 1996 to 2003


Federal Support

Title II ADAP Earmark: In response to fiscal challenges for States, Congress designated dollars specifically to State ADAPs. This Title II supplemental funding is know as the ADAP earmark. In FYs 1996 and 1997, $219 million in appropriated funds were earmarked specifically for ADAPs. In FY 1998, the earmark climbed to $285.5 million. That figure rose to $461 million for FY 1999. By FY 2003 ADAPs received $714 million, bringing total ADAP funding to over $3 billion since 1991.

Title II Support: In response to the rapid increase in program costs and greater demand for access to antiretroviral medications, some States and Territories have chosen to add some of their Title II base funds to their ADAP. In FY 2003, it is predicted that 16 States will contribute an average of 16% of their Title II base awards to their ADAP.

Title I EMA Support: Another source of funding for some ADAPs comes from voluntary allocations from Title I awards. Title I of the CARE Act funds eligible metropolitan areas (EMAs). These are geographic areas (usually cities) with a high population of HIV-infected individuals. By FY 1999, it appeared that some EMAs began to decrease their contributions to their State ADAP due to the increase in ADAP earmark dollars. If increasing drug costs and client enrollment begin to outpace ADAP earmark funding, it is uncertain if Title I programs will be able to continue this trend of decreasing contributions to State ADAPs. In FY 1998, Title I programs in 13 States contributed $28.8 million to ADAPs. By FY 2003, twelve States project that Title I will contribute just over $23 million to their ADAP.

ADAP Supplemental Grants: Beginning in FY 2001, 3 percent of the ADAP earmark is to be used for supplemental grants to "severe need" States and Territories to increase access to therapeutics. In FY 2003, 17 States and Territories received $21.4 million in supplemental funding.


State General Support

Many States also allocate general revenue or other State funds to support their ADAPs. In FY 2003, 37 States projected appropriations of approximately $165 million to their State ADAP.


Cost-Containment Strategies

Most States participate in multiple strategies designed to maximize available ADAP funds and assist the greatest number of people living with HIV/AIDS. Generally, these strategies result in savings that revert directly back into the State's ADAP budget. One example of a cost-savings method includes participation in the Section 340B Drug Discount Program, either through a point of purchase discount or through the ADAP rebate option. Other examples include negotiated discounts with wholesalers or pharmacies, purchase of insurance services for clients, and insurance recovery mechanisms for clients who have partial drug benefit coverage through Medicaid or a private insurer. For example, an ADAP might supplement a State Medicaid or insurance program that limits the number of prescriptions that can be filled per month.

In FY 1998, 24 States received $37.4 million as a result of these cost-savings mechanisms, funds that were then used to purchase additional pharmaceuticals. By FY 2003, 24 States project a total savings of nearly $112.2 million through use of cost-saving strategies and carry-over dollars.


Current and Emerging Issues

As new and rapidly changing treatments enhance individuals' overall health status and improve their quality of life, ADAPs will continue to face fiscal challenges. Most ADAPs project program growth, with increasing enrollment and utilization of emerging drug therapies. HIV Clinical Treatment Guidelines emphasizing combination antiretroviral drug therapies continue to impact the overall increase in enrollment and costs. The advent of new, more effective therapeutics require that care providers, ADAPs, and patients view HIV as a treatable and chronic disease, factors that will affect ADAP policies. ADAPs continue to explore resource opportunities such as the use of Ryan White funds to purchase health insurance policies for individuals with HIV/AIDS. Finally, continued budget constraints and the need for HIV-trained and qualified primary health care providers must be anticipated.

Table: ADAP Funding Information, FY 2003




This article was provided by U.S. Health Resources and Services Administration. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art12384.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.